Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 3200

Inclusion Criteria

Inclusion Criteria: - Patients of age =18 years who undergo isolated CABG for coronary artery disease - POAF that persists for >60 minutes or is recurrent (more than one episode) within 7 days after the index CABG surgery Exclusion Criteria: - Clinical history of either permanent, persistent or paroxysmal atrial fibrillation - Any pre-existing clinical indication for long-term OAC - Any absolute contraindication to OAC - Planned use of post-operative dual antiplatelet therapy (DAPT) a. This includes, but is not limited to, patients with recent PCI with drug-eluting or bare-metal stent. - Cardiogenic shock - Major perioperative complication* occurring between CABG and randomization a. including, but not limited to, stroke, TIA, MI, major bleeding (BARC type 4 bleeding), severe sepsis, renal failure requiring dialysis, or need for reoperation due to bleeding (e.g. pericardial tamponade). - Concomitant left atrial appendage closure during CABG - Concomitant valve surgery during CABG or prior valve surgery (including aortic, mitral, tricuspid or pulmonary) - Concomitant mitral valve annuloplasty during CABG - Concomitant carotid artery endarterectomy during CABG - Concomitant aortic root replacement during CABG - Concomitant surgery for AF during CABG - Liver cirrhosis or Child-Pugh Class C chronic liver disease - Pharmacologic therapy with an investigational drug or device within 30-days prior to randomization or plan to enroll patient in an investigational drug or device trial during participation in this trial - Pregnancy at the time of randomization - Unable or unwilling to provide inform consent - Unable or unwilling to comply with the study treatment and follow-up - Existence of underlying disease that limits life expectancy to less than one year

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Composite of death, ischemic stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism (DVT and/or PE);Any BARC type 3 or 5

Secondary Outcome Measures

Name	Time	Method
Net clinical benefit (NCB);Number of participants with Ischemic Stroke event;Number of participants with TIA event;Number of participants with MI event;Number of participants with systematic arterial thromboembolism event;Number of participants with venous thromboembolism event;Number of cardiovascular mortalities;Number of non-cardiovascular mortalities;The incidence of BARC 2 bleeding at 90 after randomization;The incidence of BARC 2 bleeding at 180 days after randomization;Number of cardiac arrhythmias